Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines

被引:2
|
作者
Breen, Laura [1 ]
Heenan, Mary [1 ]
Amberger-Murphy, Verena [1 ]
Clynes, Martin [1 ]
机构
[1] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland
关键词
p53; lung cancer; chemotherapy resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: p53 is a tumour suppressor gene, which is mutated in more than half of all tumours. Most chemotherapeutic drugs cause DNA damage, which is sensed by p53; the cell can then try to repair the damage or induce cell suicide. If the p53 machinery is defective, effective chemotherapy is made more difficult. Materials and Methods: Wild-type p53 was transfected into lung cancer cell lines with different p53 status. The transfected cells were tested for changes in sensitivity to a range of chemotherapeutic agents. Results: We observed only modest changes in the sensitivity to the chemotherapeutic agents adriamycin, taxol and carboplatin in the transfected cells lines. p53 protein was detected in a transfected clone of the cell line H1299, whose parent cells are p53 null. However, the protein did not accumulate after DNA damage, suggesting that this cell line utilises alternative pathways for responding to stress, and no longer has a functional p53 pathway. Conclusion: The results suggest that introduction of wild-type p53 alone is not sufficient to substantially alter the sensitivity of a cell line to a given chemotherapeutic agent.
引用
收藏
页码:1361 / 1364
页数:4
相关论文
共 50 条
  • [31] The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis
    Florijan, Marijana Knezovic
    Ozretic, Petar
    Bujak, Maro
    Pezze, Laura
    Ciribilli, Yari
    Kastelan, Zeljko
    Slade, Neda
    Hudolin, Tvrtko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (09) : 578.e1 - 578.e10
  • [32] Prognostic role of p53 in stage III non-small cell lung cancer
    Berghmans, T
    Mascaux, C
    Martin, B
    Ninane, V
    Sculier, JP
    ANTICANCER RESEARCH, 2005, 25 (3C) : 2385 - 2389
  • [33] TRANSACTIVATION OF P53 IN P53 MUTANT-CELL LINES IN-VIVO
    PARK, DJ
    NAKAMURA, H
    CHUMAKOV, AM
    SAID, JW
    MILLER, CW
    CHEN, DL
    KOEFFLER, HP
    BLOOD, 1993, 82 (10) : A39 - A39
  • [34] Induction of tubulin by Docetaxel is associated with p53 status in human non small cell lung cancer cell lines
    Chang, JT
    Chang, GC
    Ko, JL
    Liao, HY
    Liu, HJ
    Chen, CC
    Su, JM
    Lee, H
    Sheu, GT
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (02) : 317 - 325
  • [35] Breathing new insights into the role of mutant p53 in lung cancer
    Chen, Tianwei
    Ashwood, Lauren M.
    Kondrashova, Olga
    Strasser, Andreas
    Kelly, Gemma
    Sutherland, Kate D.
    ONCOGENE, 2025, 44 (03) : 115 - 129
  • [36] A role for MnSOD and p53 in regulating HIF-1 alpha in breast cancer cell lines
    Jetawattana, S
    Venkataraman, S
    Domann, F
    Oberley, L
    FREE RADICAL BIOLOGY AND MEDICINE, 2005, 39 : S166 - S166
  • [37] The role of functional p53 in cisplatin chemosensitivity in a panel of human ovarian cancer cell lines.
    Walton, MI
    Koshy, P
    Medlow, CJ
    Sharp, S
    Kelland, LR
    Sharp, S
    Titley, J
    BRITISH JOURNAL OF CANCER, 1998, 78 : 19 - 19
  • [38] Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression
    Puchades, Maja
    Nilsson, Carol L.
    Emmett, Mark R.
    Aldape, Kenneth D.
    ji, Yonge Ji
    Lang, Frederick F.
    Liu, Ta-Jen
    Conrad, Charles A.
    JOURNAL OF PROTEOME RESEARCH, 2007, 6 (02) : 869 - 875
  • [39] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Jianli Chen
    Nashwa Emara
    Charalambos Solomides
    Hemant Parekh
    Henry Simpkins
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1103 - 1111
  • [40] Resistance to platinum-based chemotherapy in lung cancer cell lines
    Chen, Jianli
    Emara, Nashwa
    Solomides, Charalambos
    Parekh, Hemant
    Simpkins, Henry
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1103 - 1111